Welcome to our dedicated page for IceCure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical Ltd. reported that director Chan Vincent Chun Hung ceased serving on the board on August 12, 2026. This exit Form 4 states that, following this departure, he is no longer subject to Section 16 reporting obligations for IceCure Medical Ltd., and it reports no insider transactions or holdings.
IceCure Medical Ltd. reports that its board of directors approved an increase in the ordinary shares reserved for its 2024 Employee Equity Incentive Plan. The reserve rose by 2,500,000 ordinary shares, from 112,667 to 2,612,667 ordinary shares available for future equity awards to employees.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 300,332 ordinary shares of IceCure Medical Ltd., representing 9.99% of the class. All of these shares are held with shared voting and dispositive power, with no sole voting or dispositive power reported for either reporting person.
Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises voting and investment power over these securities under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may be deemed to beneficially own the same securities. The Master Fund has the right to receive dividends and sale proceeds for the reported securities, while it disclaims beneficial ownership because it cannot vote or dispose of them under the Investment Management Agreement.
IceCure Medical Ltd., an Israel-based medical device company focused on liquid-nitrogen cryoablation systems (including its ProSense system for low-risk breast cancer), has filed a post-effective amendment to a Form F-1 to update financials and maintain effectiveness of a resale registration.
The registration covers the resale by selling shareholders of up to 533,334 Ordinary Shares, all issuable upon exercise of previously issued Series B and Series C warrants. IceCure is not selling any shares and will not receive proceeds from share resales, but will receive cash equal to the exercise price of any warrants exercised, intended for working capital and general corporate purposes.
The Series B and C warrants held by one investor were amended in June 2026, cutting the exercise price to $3.00 per share and extending expirations, subject to shareholder approval obtained on August 6, 2026. A 30‑for‑1 reverse share split became effective on Nasdaq on June 4, 2026, and shares and per‑share data are presented on a post‑split basis.
IceCure Medical Ltd. filed Post-Effective Amendment No. 4 to a Form F-1 to maintain registration for the issuance of up to 324,802 Ordinary Shares upon exercise of outstanding warrants from a prior rights offering. This includes warrants for up to 323,440 shares at $30.00 per share and pre-funded warrants for up to 1,362 shares at $0.003 per share. If all such warrants are exercised for cash, IceCure expects approximately $9.7 million in net proceeds for working capital and general corporate purposes, and total shares outstanding would rise from 4,638,381 to 4,962,787.
IceCure is a commercial-stage Israeli medical device company focused on liquid-nitrogen cryoablation systems for tumor treatment. Its ProSense system has U.S. FDA marketing authorization for local treatment of low-risk breast cancer in women aged 70 and above with adjuvant endocrine therapy. As an emerging growth company and foreign private issuer, IceCure uses reduced U.S. reporting requirements. The company reports that, assuming full warrant exercise, net tangible book value would increase to $4.36 per share, while warrant holders would experience dilution of $25.52 per share relative to the warrant exercise price.
IceCure Medical Ltd. reported first-half 2026 revenue of $1.818 million, up 45% from $1.250 million a year earlier, driven by higher system and disposable probe sales and increased U.S. and international demand. Gross profit rose to $548,000, a 30% gross margin.
Despite the growth, IceCure posted an operating loss of $8.671 million and a net loss of $8.775 million, with negative operating cash flow of $8.148 million. Management states that recurring losses, cash burn and funding needs raise substantial doubt about its ability to continue as a going concern. Cash and cash equivalents increased to $12.034 million as of June 30, 2026, supported by $11.319 million of net financing inflows from ATM sales and a June 2026 private placement of pre-funded and other warrants. Shareholders’ equity improved to $11.896 million after these capital raises.
IceCure Medical Ltd. reported a Board change. Vincent Chun Hung Chan resigned as a director, effective August 14, 2026, and the company stated his resignation was not related to any disagreement regarding operations, policies or practices. The Board appointed David Salton as an independent Class II director until the 2027 annual general meeting of shareholders.
Salton will serve on the Compensation Committee, the Audit Committee and Financial Statement Examination Committee. IceCure expects to enter into its standard indemnification and exemption agreement with him, on the same terms as for other directors and executive officers, and disclosed that there are no related party transactions involving him requiring disclosure under Item 7.B of Form 20-F. His background includes CEO roles at medical technology start-ups and multiple prior independent directorships.
IceCure Medical Ltd. convened a Special General Meeting of Shareholders on August 6, 2026. The meeting was initially adjourned at 5:00 p.m. (Israel time) because a quorum was not present, but the adjourned meeting was held at 6:30 p.m. (Israel time) once a quorum was reached.
At the adjourned meeting, shareholders voted on and approved the agenda item described in the proxy statement furnished to the SEC on July 2, 2026. The Form 6-K is incorporated by reference into the company’s registration statements on Form F-3 (File Nos. 333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-270982, 333-264578, 333-262620 and 333-281587).
IceCure Medical Ltd. is calling a remote Special General Meeting on August 6, 2026 to seek shareholder approval for amendments to certain outstanding Series B and Series C warrants issued in a March 2026 private placement.
The proposed changes would cut the warrants’ exercise price from $16.50 per share to $3.00 per share and extend their terms, so that Series B warrants would expire on June 18, 2031 and Series C warrants on June 18, 2027. The board states that lower exercise prices and longer durations are expected to increase the likelihood of exercise and potential capital inflows, and to keep the investor engaged with the company.
The company notes that these amendments may lead to the issuance of 20% or more of its outstanding share capital at terms not considered on-market under Israeli law, which is why shareholder approval by a simple majority at the meeting is required.